{"id":390511,"date":"2018-12-24T00:00:00","date_gmt":"2018-12-24T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfcg0001-2018-biopharma-alzheimers-disease-disease-landscape-and-forecast-g7-2018\/"},"modified":"2026-04-25T11:37:11","modified_gmt":"2026-04-25T11:37:11","slug":"dlsfcg0001-2018-biopharma-alzheimers-disease-disease-landscape-and-forecast-g7-2018","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfcg0001-2018-biopharma-alzheimers-disease-disease-landscape-and-forecast-g7-2018\/","title":{"rendered":"Alzheimer&#8217;s Disease | Disease Landscape and Forecast | G7 | 2018"},"content":{"rendered":"<p>The Alzheimer\u2019s disease (<abbr title=\"Alzheimer's disease\">AD<\/abbr>) market today comprises a handful of symptomatic options that offer only modest efficacy of limited duration, leaving ample room for novel, more-effective alternatives\u2014in particular, disease-modifying therapies capable of slowing disease progression. As the baby boomer generation ages, we forecast a rapidly growing pool of patients suffering from this devastating condition, a trend that will simultaneously increase the treatment-eligible patient pool and impose a new strain on healthcare resources. Considering the huge unmet need, many drug developers continue to invest heavily in this space, despite a perennially high rate of attrition. Based on the latest developments and expert insights, we forecast the launch of three potential disease-modifying therapies (<abbr title=\"disease-modifying therapy\">DMT<\/abbr>s) targeting the amyloid cascade\u2014Biogen\/Neurimmune\u2019s aducanumab, Roche\/Genentech\/AC Immune\u2019s crenezumab, and Roche\/MorphoSys\u2019s gantenerumab\u2014which will dramatically expand the market for\u00a0<abbr title=\"Alzheimer's disease\">AD<\/abbr>\u00a0therapies market over the next ten years. Additionally, we forecast the launch of two behavioral therapies, Avanir\/Otsuka\u2019s AVP-786 and Lundbeck\/Otsuka\u2019s Rexulti, for the treatment of agitation associated with\u00a0<abbr title=\"Alzheimer's disease\">AD<\/abbr>, a burdensome symptom affecting both patients and caregivers. However, owing to as-yet uncertain clinical benefits from any of the emerging candidates and to lingering questions about the clinical efficacy, safety, and fundamental launch prospects of putative\u00a0<abbr title=\"disease-modifying therapy\">DMT<\/abbr>s, we expect investigational products will only partially fulfill the need for therapeutic advances should they launch\u2014an outcome that is far from guaranteed.<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul>\n<li>How large is the treatable\u00a0<abbr title=\"Alzheimer's disease\">AD<\/abbr>\u00a0population, and how will diagnosis\/drug-treatment rates change over time? What will the impact of\u00a0<abbr title=\"disease-modifying therapy\">DMT<\/abbr>s be on diagnosis\/drug treatment and in which populations?<\/li>\n<li>What pipeline products are the most promising, and what sales\/uptake could they secure in\u00a0<abbr title=\"Alzheimer's disease\">AD<\/abbr>? What is the forecast for emerging\u00a0<abbr title=\"disease-modifying therapy\">DMT<\/abbr>s such as Biogen\u2019s aducanumab or agents to treat agitation in\u00a0<abbr title=\"Alzheimer's disease\">AD<\/abbr>\u00a0such as Avanir\/Otsuka\u2019s AVP-786?<\/li>\n<li>What are the drivers and constraints in the\u00a0<abbr title=\"Alzheimer's disease\">AD<\/abbr>\u00a0therapy market, and how might they change over the forecast period as premium-priced agents enter the market?<\/li>\n<\/ul>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<p>Disease Landscape &#038; Forecast: Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.<\/p>\n","protected":false},"template":"","class_list":["post-390511","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-alzheimers-disease","biopharma-date-920"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390511","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390511\/revisions"}],"predecessor-version":[{"id":576663,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390511\/revisions\/576663"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390511"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}